Skip to content

An Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix)

A Randomized Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix) in the Prevention of Hypertrophic Scar in Subjects Undergoing Caesarean Section

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01004536
Enrollment
47
Registered
2009-10-30
Start date
2010-10-31
Completion date
2011-02-28
Last updated
2010-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cicatrix

Brief summary

Silicone gel is a self-drying silicone polymer that forms thin film after application onto the skin. Because silicone film is a medical device, silicone gel is also regarded as a medical device. Silicone gel has been on the market for many years for the management of scar in the phase of treatment as well as in the phase of prevention. In contrast to other methods that are expensive, invasive or inconvenient, silicone gel is convenient, non-invasive and also reasonably priced. However, the number of well-designed clinicial trials for efficacy and safety are not enough to provide robust evidences in making clinical decisions for scar management options. In a prospective, multi-center, investigator-blind randomized half-split study for patients undergoing cesarean sections, the investigators attempt to provide valid information for the efficacy and safety of silicone gel in the prevention phase of scar.

Detailed description

Prospective subjects will be enrolled in the trial when eligibility screening and informed consent were made. One day after stitch out for cesarean sections, subjects will be asked to start applying silicone gel as the instruction to the randomly designated half of the wound 2 times a day for 12 weeks. Subjects are asked to make visits on week 4, 8, and 12 for efficacy, safety and compliance evaluations. Obstetricians, dermatologists and medical imaging specialists are involved in the trial for the evaluation of efficacy, safety and compliance. Sample size calculation as well as statistical analysis will be conducted by a designated statistician. Study product will be provided by the manufacturer at no cost and patient visits and relevant lab exams will be conducted free of charge.

Interventions

twice daily application onto designated half of cesarean section wound for 12 weeks

OTHERno treatment

left untreated during the study period

Sponsors

Seoul National University Hospital
CollaboratorOTHER
Kyunghee University Medical Center
CollaboratorOTHER
Inovail
CollaboratorUNKNOWN
Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant female of 20-45 in ages equal to or beyond 34th of pregnancy * Those who understand and agree on the trial conditions

Exclusion criteria

* Keloid (by present and past medical history) * Secondary infection, and/or dermatitis in and around c/s wound * Hypersensitivity to the study agent * Diabetes * (Pre)eclampsia

Design outcomes

Primary

MeasureTime frame
summation of scar scores of modified Vancouver Scar Scaleweek 12

Secondary

MeasureTime frame
summation of scar scores of mVSS 4 and 8 weeks after applicationweeks 4, 8, 12
scar thickness 12 weeks after applicationweeks 4, 8, 12
subjective satisfaction 12 weeks after application (VAS)weeks 4, 8, 12
tolerability 4, 8, 12 weeks after application (index3)weeks 4, 8, 12

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026